SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor for the co-development and commercialisation of resomelagon for dengue and other viral infections in Brazil.
We view this agreement positively, as it builds on SynAct’s existing RESOVIR research collaboration and ongoing RESOVIR-2 Phase II dengue study, adding local regulatory, development and commercial capabilities in the world’s largest dengue market and offering an optimised route to commercialisation.
The proposed 50:50 profit and development cost split with additional sales milestones offers more aligned economics than a conventional licence agreement, while preserving SynAct’s control of the asset outside of Brazil.
We believe the agreement provides useful external validation of resomelagon’s potential in acute inflammation and adds strategic optionality beyond the core advanced rheumatoid arthritis (RA) opportunity. A definitive agreement is targeted in the coming months.